MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtha.2026.03.006

Медицинская библиотека · Journal of thrombosis and haemostasis : JTH · 2026

Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19: a randomized clinical trial.

Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP-CAP) Investigators, Bradbury Charlotte A, McVerry Bryan J, Lawler Patrick R, Angus Derek C, Annane Djillali, Arabi Yaseen M, Aryal Diptesh, Au Carly, Beane Abigail, Berry Scott M, Berry Lindsay R, Best-Lane Janis, Bihari Shailesh, Bonten Marc, Brunkhorst Frank, Burrell Aidan, Buxton Meredith, Carrier Marc, Cecconi Maurizio, Cheng Allen C, Cove Matthew, Derde Lennie P G, Detry Michelle A, Estcourt Lise J, Fergusson Dean A, Fitzgerald Mark, Fowler Rob A, Goligher Ewan C, Green Cameron, Haniffa Rashan, Harrison David A, Hays Leanne M C, Higgins Alisa M, Hills Thomas, Horvat Christopher M, Huang David T, Hunt Beverley J, Ichihara Nao, Jayakumar Devachandran, Keattch Stephanie, Kumar Anand, Laffan Michael A, Lamontagne Francois, Leeper Christine M, Lewis Roger J, Lorenzi Elizabeth, Lother Sylvain A, Marshall John C, McArthur Colin J, McAuley Daniel F, McGlothlin Anna, McGuinness Shay P, McQuilten Zoe K, Middeldorp Saskia, Morpeth Susan, Mouncey Paul R, Murthy Srinivas, Neal Matthew D, Nichol Alistair D, Parke Rachael L, Parker Jane C, Peters Svenja, Reyes Lusi Felipe, Rowan Kathryn, Saito Hiroki, Santos Marlene, Saunders Christina T, Schutgens Roger E G, Seymour Christopher W, Hari Manu Shankar, Singh Vanessa, Stanworth Simon J, Turgeon Alexis F, Turner Anne M, van de Veerdonk Frank L, Gordon Anthony C, Webb Steve A, Zarychanski Ryan

СтатьяРандомизированное исследованиеМногоцентровое исследованиеAdaptive Clinical TrialПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

The optimal thromboprophylaxis among critically ill adults with COVID-19 is uncertain.

OBJECTIVES

To determine the effectiveness and safety of intermediate-dose heparin compared with standard low-dose thromboprophylaxis.

METHODS

In an ongoing adaptive platform trial (randomized embedded multifactorial adaptive platform for community-acquired pneumonia), critically ill patients with COVID-19 were randomized to intermediate-dose heparin or standard low-dose thromboprophylaxis. Interventions were continued in hospital for up to 14 days. The primary endpoint was organ support-free days (OSFDs), an ordinal outcome combining in-hospital survival and the number of days free of intensive care unit-based respiratory or cardiovascular organ support through 21 days. The primary analysis was an adjusted Bayesian hierarchical cumulative logistic model. An odds ratio (OR) > 1.0 represents an improved outcome with intermediate-dose heparin.

RESULTS

Between April 27, 2021 and November 25, 2023, 1255 critically ill adults with COVID-19 were enrolled from 78 sites in 15 countries, of whom 1254 completed follow-up (n = 572 intermediate-dose, n = 682 low-dose). Enrollment was terminated prior to reaching a prespecified statistical trigger due to declining case numbers and slow recruitment. Median age was 59 years, and 36.7% were female (n = 461/1255). The probability that intermediate-dose heparin improved OSFDs was 73.5% (OR, 1.06; 95% credible interval, 0.87, 1.30), which did not meet the prespecified superiority threshold of 99%. Hospital survival was 77.1% (441/572) and 76.7% (523/682) in the intermediate- and low-dose heparin groups, respectively (median adjusted OR, 1.14; 95% credible interval, 0.86, 1.52). Major bleeding occurred in 10 of 572 (1.7%) and 14 of 682 (2.1%) patients receiving intermediate and standard low doses, respectively.

CONCLUSION

Intermediate-dose heparin did not improve OSFDs or survival compared with standard thromboprophylaxis in critically ill patients with COVID-19. (ClinicalTrials.gov number: CT02735707).

Для цитирования: Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP-CAP) Investigators, Bradbury Charlotte A, McVerry Bryan J, Lawler Patrick R, Angus Derek C, Annane Djillali, Arabi Yaseen M, Aryal Diptesh, Au Carly, Beane Abigail, Berry Scott M, Berry Lindsay R, Best-Lane Janis, Bihari Shailesh, Bonten Marc, Brunkhorst Frank, Burrell Aidan, Buxton Meredith, Carrier Marc, Cecconi Maurizio, Cheng Allen C, Cove Matthew, Derde Lennie P G, Detry Michelle A, Estcourt Lise J, Fergusson Dean A, Fitzgerald Mark, Fowler Rob A, Goligher Ewan C, Green Cameron, Haniffa Rashan, Harrison David A, Hays Leanne M C, Higgins Alisa M, Hills Thomas, Horvat Christopher M, Huang David T, Hunt Beverley J, Ichihara Nao, Jayakumar Devachandran, Keattch Stephanie, Kumar Anand, Laffan Michael A, Lamontagne Francois, Leeper Christine M, Lewis Roger J, Lorenzi Elizabeth, Lother Sylvain A, Marshall John C, McArthur Colin J, McAuley Daniel F, McGlothlin Anna, McGuinness Shay P, McQuilten Zoe K, Middeldorp Saskia, Morpeth Susan, Mouncey Paul R, Murthy Srinivas, Neal Matthew D, Nichol Alistair D, Parke Rachael L, Parker Jane C, Peters Svenja, Reyes Lusi Felipe, Rowan Kathryn, Saito Hiroki, Santos Marlene, Saunders Christina T, Schutgens Roger E G, Seymour Christopher W, Hari Manu Shankar, Singh Vanessa, Stanworth Simon J, Turgeon Alexis F, Turner Anne M, van de Veerdonk Frank L, Gordon Anthony C, Webb Steve A, Zarychanski Ryan. Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19: a randomized clinical trial.. Journal of thrombosis and haemostasis : JTH. 2026. DOI: 10.1016/j.jtha.2026.03.006.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.